TY - JOUR
T1 - Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients
AU - Sethi, Sanjeev
AU - Debiec, Hanna
AU - Madden, Benjamin
AU - Vivarelli, Marina
AU - Charlesworth, M. Cristine
AU - Ravindran, Aishwarya
AU - Gross, Lou Ann
AU - Ulinski, Tim
AU - Buob, David
AU - Tran, Cheryl L.
AU - Emma, Francesco
AU - Diomedi-Camassei, Francesca
AU - Fervenza, Fernando C.
AU - Ronco, Pierre
N1 - Funding Information:
We thank the Mayo Clinic Genome Facility-Proteomics Core (a shared resource of the Mayo Clinic Cancer Center [NCI P30 CA15083]), Department of Laboratory Medicine and Pathology, and the Pathology Research Core, Mayo Clinic. PR is a recipient of European Research Council ERC-2012-ADG_20120314 grant 322947, 7th Framework Programme of the European Community contract 2012-305608 (European Consortium for High-Throughput Research in Rare Kidney Diseases), and the National Research Agency grant MNaims (ANR-17- CE17-0012-01). We are very grateful to Stéphane Burtey (Department of Nephrology) and Laurent Daniel (Department of Pathology), both in Marseille, France, for providing patient 5. We thank Jason Theis (Department of Laboratory Medicine and Pathology, Mayo Clinic) for going through MS amyloid database to screen for Sema3B. We are greatly indebted to the clinicians who took care over the last 20 years, of the patients with primary MN (control subjects) in the Department of Nephrology and Dialysis and in the Nephrology Day Hospital at Tenon Hospital, Paris, and in the Division of Nephrology and Dialysis at Bambino Gesù Pediatric Hospital, Rome, and to Isabelle Brocheriou (MD, PhD) from the Department of Pathology, Pitié Salpêtrière Hospital, Paris, and to Nadhir Yousfi (PhD) for help in WB experiments. We thank Romain Morichon and Perrine Frère, Confocal Microscopy Platform, Saint-Antoine Hospital and Tenon Hospital, respectively; Marie-Christine Verpont, Electron Microscopy Platform, Tenon Hospital, Paris; and Eva Compérat and all staff members of the Tenon Hospital Biological Resource Center (BRC CANCER HUEP- Paris) for their help in centralizing and managing biologic data collection.
Funding Information:
We thank the Mayo Clinic Genome Facility-Proteomics Core (a shared resource of the Mayo Clinic Cancer Center [NCI P30 CA15083]), Department of Laboratory Medicine and Pathology, and the Pathology Research Core, Mayo Clinic. PR is a recipient of European Research Council ERC-2012-ADG_20120314 grant 322947, 7th Framework Programme of the European Community contract 2012-305608 (European Consortium for High-Throughput Research in Rare Kidney Diseases), and the National Research Agency grant MNaims (ANR-17- CE17-0012-01). We are very grateful to St?phane Burtey (Department of Nephrology) and Laurent Daniel (Department of Pathology), both in Marseille, France, for providing patient 5. We thank Jason Theis (Department of Laboratory Medicine and Pathology, Mayo Clinic) for going through MS amyloid database to screen for Sema3B. We are greatly indebted to the clinicians who took care over the last 20 years, of the patients with primary MN (control subjects) in the Department of Nephrology and Dialysis and in the Nephrology Day Hospital at Tenon Hospital, Paris, and in the Division of Nephrology and Dialysis at Bambino Ges? Pediatric Hospital, Rome, and to Isabelle Brocheriou (MD, PhD) from the Department of Pathology, Piti? Salp?tri?re Hospital, Paris, and to Nadhir Yousfi (PhD) for help in WB experiments. We thank Romain Morichon and Perrine Fr?re, Confocal Microscopy Platform, Saint-Antoine Hospital and Tenon Hospital, respectively; Marie-Christine Verpont, Electron Microscopy Platform, Tenon Hospital, Paris; and Eva Comp?rat and all staff members of the Tenon Hospital Biological Resource Center (BRC CANCER HUEP- Paris) for their help in centralizing and managing biologic data collection. SS and FCF designed the study. SS wrote the manuscript and interpreted the kidney biopsy, clinical, IHC, and MS data. BM and CC performed the laser microdissection and mass spectrometry. AR helped in gathering clinical data. LG performed the IHC. HD, DB, and FDC provided tissue for the validation cohorts. HD performed the immunofluorescence, confocal studies, and Western blot analysis. PR, MV, FE, and TU provided clinical information. The manuscript was drafted and written by the first author, with input as appropriate from the investigators.
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2020/11
Y1 - 2020/11
N2 - Membranous nephropathy results from subepithelial antigen-antibody complex deposition along the glomerular basement membrane. Although PLA2R, THSD7A, and NELL-1 account for a majority (about 80%) of the target antigens, the target antigen in the remaining cases is not known. Using laser microdissection of PLA2R-negative glomeruli of patients with membranous nephropathy followed by mass spectrometry we identified a unique protein, Semaphorin 3B, in three cases. Mass spectrometry failed to detect Semaphorin-3B in 23 PLA2R-associated cases of membranous nephropathy and 88 controls. Semaphorin 3B in all three cases was localized to granular deposits along the glomerular basement membrane by immunohistochemistry. Next, an additional eight cases of Semaphorin 3B-associated membranous nephropathy were identified in three validation cohorts by immunofluorescence microscopy. In four of 11 cases, kidney biopsy also showed tubular basement membrane deposits of IgG on frozen sections. Confocal microscopy showed that both IgG and Semaphorin 3B co-localized to the glomerular basement membrane. Western blot analysis of five available sera showed reactivity to reduced Semaphorin 3B in four of four patients with active disease and no reactivity in one patient in clinical remission; there was also no reactivity in control sera. Eight of the 11 cases of Semaphorin 3B-associated membranous nephropathy were pediatric cases. Furthermore, in five cases, the disease started at or below the age of two. Thus, Semaphorin 3B-associated membranous nephropathy appears to be a distinct type of disease; more likely to be present in pediatric patients.
AB - Membranous nephropathy results from subepithelial antigen-antibody complex deposition along the glomerular basement membrane. Although PLA2R, THSD7A, and NELL-1 account for a majority (about 80%) of the target antigens, the target antigen in the remaining cases is not known. Using laser microdissection of PLA2R-negative glomeruli of patients with membranous nephropathy followed by mass spectrometry we identified a unique protein, Semaphorin 3B, in three cases. Mass spectrometry failed to detect Semaphorin-3B in 23 PLA2R-associated cases of membranous nephropathy and 88 controls. Semaphorin 3B in all three cases was localized to granular deposits along the glomerular basement membrane by immunohistochemistry. Next, an additional eight cases of Semaphorin 3B-associated membranous nephropathy were identified in three validation cohorts by immunofluorescence microscopy. In four of 11 cases, kidney biopsy also showed tubular basement membrane deposits of IgG on frozen sections. Confocal microscopy showed that both IgG and Semaphorin 3B co-localized to the glomerular basement membrane. Western blot analysis of five available sera showed reactivity to reduced Semaphorin 3B in four of four patients with active disease and no reactivity in one patient in clinical remission; there was also no reactivity in control sera. Eight of the 11 cases of Semaphorin 3B-associated membranous nephropathy were pediatric cases. Furthermore, in five cases, the disease started at or below the age of two. Thus, Semaphorin 3B-associated membranous nephropathy appears to be a distinct type of disease; more likely to be present in pediatric patients.
KW - Semaphorin 3B
KW - kidney biopsy
KW - mass spectrometry
KW - membranous nephropathy
UR - http://www.scopus.com/inward/record.url?scp=85088129988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088129988&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.05.030
DO - 10.1016/j.kint.2020.05.030
M3 - Article
C2 - 32534052
AN - SCOPUS:85088129988
SN - 0085-2538
VL - 98
SP - 1253
EP - 1264
JO - Kidney International
JF - Kidney International
IS - 5
ER -